SINGAPORE - AstraZeneca will invest US$1.5 billion in building a manufacturing facility in Singapore for antibody drug conjugates (ADCs), the biopharmaceutical giant announced Monday. AstraZeneca aims ...
SINGAPORE, May 20 (Xinhua ... biopharmaceutical giant announced Monday. AstraZeneca aims to begin design and construction of the manufacturing facility by the end of this year, with targeted ...
CEO Pascal Soriot is working to ensure AstraZeneca can independently supply drugs to major markets as the US pushes to reduce ...
AstraZeneca plans to build a $1.5 billion manufacturing facility in Singapore to produce a promising category of ...
British pharmaceutical company AstraZeneca announced on May 20 its intention to build a 1.5 billion USD facility in Singapore ...
AstraZeneca says it will invest 1.5 billion U.S. dollars in building a manufacturing facility in Singapore for antibody drug conjugates (ADCs ... Ahmed Ododo of Kogi State has vowed to deploy ...
British pharmaceutical company AstraZeneca announced on May 20 its intention to build a 1.5 billion USD billion facility in ...
Global biopharmaceutical company AstraZeneca intends to build a US$1.5bil manufacturing facility in Singapore, the company ...
AstraZeneca intends to build a $1.5 billion next-generation manufacturing facility in Singapore to produce ADCs for cancer ...
The manufacturing facility, supported by Singapore's Economic Development Board, is for antibody drug conjugates, and will be ...